SciSparc Ltd. (SPRC) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
SPRC currently has 365K outstanding shares. with significant dilution risk as 129M authorized shares could dilute existing holders by 35428.5%. The company has significantly diluted shareholders by 222.96% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Apr 29, 2026 |
20-F filing | 0.4M shares outstanding |
370K | 130M |
| Apr 24, 2025 |
20-F filing | 10.8M shares outstanding |
11M | 130M |
| Mar 25, 2025 |
F-3 filing: This F-3 filing relates to an offering of Ordinary Shares by selling shareholders, consisting of debenture shares and warrant shares. The company will not receive any proceeds from the sale of these shares, but will receive proceeds from the cash exercise of warrants, which they intend to use for working capital and general corporate purposes. |
11M | 130M |
| Jan 21, 2025 |
POS AM filing: This prospectus relates to the offer and sale of up to 20,604,809 of our ordinary shares by YA II PN, LTD. |
11M | 68M |
| Aug 28, 2024 |
F-1 filing: This F-1 filing relates to the offer and sale of up to 21,000,000 ordinary shares by YA II PN, LTD. pursuant to a Standby Equity Purchase Agreement (SEPA). |
10M | 89M |
| Jun 17, 2024 |
POS AM filing: This prospectus relates to the offer and sale of up to 4,422,435 of our ordinary shares by YA II PN, LTD., a Cayman Islands exempt limited partnership. |
3.3M | 68M |
| May 02, 2024 |
POS AM filing: This prospectus relates to the offer and sale of up to 4,422,435 of our ordinary shares by YA II PN, LTD. |
3.1M | 68M |
| Apr 01, 2024 |
20-F filing | 0.7M shares outstanding |
710K | 74M |
| Feb 27, 2024 |
F-1 filing: This F-1 filing registers for resale up to 5,402,887 ordinary shares by selling shareholder YA II PN, LTD., consisting of (i) 55,293 Commitment Shares and (ii) up to 5,347,594 Ordinary Shares that we may sell to YA under the SEPA from time to time. |
1.1M | 74M |
| Nov 03, 2023 |
F-3 filing: Resale of up to 3,860,216 ordinary shares issuable upon exercise of pre-funded warrants by the selling shareholder. |
520K | 68M |
| May 01, 2023 |
20-F filing | 6.8M shares outstanding |
6.8M | 64M |
| Mar 09, 2023 |
POS AM filing: This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of up to 2,809,494 ordinary shares. |
6.9M | 64M |
| Feb 17, 2023 |
F-3 filing: SciSparc Ltd. may offer and sell from time to time in one or more offerings up to the total amount of $50,000,000 of its ordinary shares, warrants or units comprising a combination of ordinary shares and warrants. |
6.9M | 64M |
| Jul 07, 2022 |
F-3 filing: This F-3 filing relates to the resale of up to 10,638,300 ordinary shares by the selling shareholder, consisting of shares held, shares issuable upon exercise of pre-funded warrants, and shares issuable upon the exercise of ordinary warrants. |
6.7M | 11M |
| Apr 28, 2022 |
20-F filing | 3.1M shares outstanding |
3.1M | 0 |
| Apr 28, 2022 |
POS AM filing: This prospectus relates to the issuance of up to 666,400 ordinary shares upon the exercise of warrants to purchase 666,400 ordinary shares, which are exercisable at an exercise price of $5.02 per ADS, and were exercisable immediately upon issuance and expire on November 23, 2025. |
3.2M | 0 |
| Oct 08, 2021 |
POS AM filing: This prospectus relates to the resale of up to 2,809,494 ordinary shares by selling shareholders, including shares held, shares issuable upon exercise of warrants, and shares issuable upon exercise of pre-funded warrants. |
2.3M | 0 |
| Aug 27, 2021 |
POS AM filing: This prospectus relates to the issuance of up to 1,454,794 ordinary shares upon the exercise of warrants to purchase 1,454,794 Ordinary Shares, which are exercisable at an exercise price of $5.02 per ADS, and were exercisable immediately upon issuance and expire on November 23, 2025. |
2.3M | 2.9M |
| Aug 27, 2021 |
POS AM filing: This prospectus relates to the issuance of up to 1,454,794 ordinary shares upon the exercise of warrants to purchase 1,454,794 Ordinary Shares that were issued as part of a public offering of units consisting of ADSs and warrants, which are exercisable at an exercise price of $5.02 per ADS, and were exercisable immediately upon issuance and expire on November 23, 2025. |
2.3M | 2.9M |
| Apr 21, 2021 |
F-1 filing: This F-1 filing relates to the resale of American Depositary Shares representing ordinary shares and warrants by selling shareholders. |
290M | 2.9M |
| Mar 31, 2021 |
POS AM filing: This prospectus relates to the issuance of up to 1,588,514 American Depositary Shares upon the exercise of warrants to purchase 1,588,514 ADSs, which are exercisable at an exercise price of $5.02 per ADS, and were exercisable immediately upon issuance and expire on November 23, 2025. |
280M | 0 |
| Mar 31, 2021 |
POS AM filing: This prospectus relates to the issuance of up to 1,588,514 American Depositary Shares upon the exercise of warrants to purchase 1,588,514 ADSs, which are exercisable at an exercise price of $5.02 per ADS and expire on November 23, 2025. |
280M | 0 |
| Mar 30, 2021 |
20-F filing | 145.1M shares outstanding |
150M | 0 |
| Jun 15, 2020 |
20-F filing | 228.8M shares outstanding |
230M | 0 |
| Jan 31, 2020 |
F-1 filing: Therapix Biosciences Ltd. is offering American Depositary Shares and warrants to purchase American Depositary Shares. |
290M | 0 |